GlassScriptPhysician profile
Teresa Chavez
NPI 1669515680
$1,422.98
in general payments reported to CMS, 2019-2025
24 companies · $688 in 2025
The $688 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $15.00 · 2021: $131 · 2022: $74.58 · 2023: $78.83 · 2024: $214 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $501.44 | 2019-2025 | Skyrizi |
| Actelion Pharmaceuticals US, INC. | $100.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.69 | 2023-2024 | Cyltezo, Jardiance |
| Abbott Laboratories | $72.18 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $67.44 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $59.87 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $58.80 | 2022-2024 | Nucala |
| Lilly USA, LLC | $49.20 | 2025 | Mounjaro, Zepbound |
| Radius Health, INC. | $49.18 | 2024-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $41.49 | 2019 | |
| Mannkind Corporation | $40.46 | 2024-2025 | |
| Amgen INC. | $36.28 | 2020-2025 | Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $34.01 | 2025 | Cuvitru |
| Genzyme Corporation | $30.99 | 2025 | |
| Janssen Biotech, INC. | $26.61 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24.11 | 2024 | Dupixent |
| Recordati_rare_diseases_inc. | $22.39 | 2025 | Isturisa |
| Antares Pharma, INC. | $22.25 | 2024 | Xyosted |
| Dexcom, INC. | $21.91 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $20.19 | 2025 | Cologuard Collection Kit |
| Insulet Corporation | $19.34 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $18.55 | 2019 | |
| Sumitomo Pharma America, INC. | $15.43 | 2025 | Gemtesa |
| Medexus Pharma, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.